Press

Next-Gen Avisi Technologies Aims for “One and Done” in a MIGS Device

Some medtech start-ups begin with an inventor with a novel idea; others seek out an unmet clinical need looking for a solution. Avisi Technologies began with market research, that is, a direct appeal to glaucoma specialists to determine what they were missing in their tool kits, and specifically, how the current generation of devices for minimally invasive […]

Avisi Technologies featured at LSI’s 2024 US Emerging Medtech Summit. Dr. Catherine Mohr delivers the keynote presentation.

Avisi Technologies Featured at LSI’s 2024 US Emerging Medtech Summit in Keynote Presentation

Summary of Avisi Involvement as Presenting Company 2024 and 2023 Panel Representation Avisi Technologies returned to the 2024 US Emerging Medtech Summit with updates about the development of VisiPlate, a nanotechnology-enabled aqueous shunt for the treatment of glaucoma. Avisi generated buzz in the Life Science Intelligence (LSI) community by announcing exclusive clinical data, showing promising […]

Illustration of a doctor examining a patient's eye for glaucoma, representing the work of the South African Glaucoma Society and advancements in glaucoma treatment.

VisiPlate® Aqueous Shunt Safety and Effectiveness data from VITA Clinical Trial to be presented at the 2024 South Africa Glaucoma Society Annual Congress

Interim trial results demonstrate the safety and effectiveness of VisiPlate® as a standalone treatment for primary open-angle glaucoma. REDWOOD CITY, Calif., (May 14, 2024) – Avisi Technologies, Inc., an ophthalmic-focused medical device manufacturer, is developing a portfolio of ophthalmic treatments based on a novel metamaterial technology. Avisi’s flagship product, VisiPlate, is a nanotechnology-enabled implant […]

Avisi Technologies, Junkosha Award, Innovation

Avisi Technologies Shortlisted for Junkosha Innovator of the Year Award

Avisi Technologies has been shortlisted for Junkosha’s second-year Innovator of the Year Award program. This year had a tremendous number of applicants with Avisi Technologies being 1 of the 11 shortlisted to impress the panel of expert judges chosen for their vast industry experience in medical devices. The winning company will be awarded a $25,000 […]

Professional woman, a leader in Healthtech, in business attire smiling at the camera.

Healthtech Leader of the Month

Avisi, a trailblazing medical device company, is developing VisiPlate, a nanotechnology-enabled aqueous shunt designed to treat glaucoma. Working closely with ophthalmologists and experts, Avisi is committed to introducing a reliable, safe and effective solution for glaucoma patients.

Scientist examining a test tube in a laboratory setting during Avisi Technologies' seed round.

Money Moves: Avisi Technologies raised a seed round

The company — a 2020 RealLIST Startups honoree — aims to treat open-angle glaucoma with an ocular implant that’s designed to remove excess fluid from inside the eye. Its recent funding injection totals just over $4 million.